Vitiligo pp 345-352 | Cite as

PUVA and Related Treatments

  • Agustin AlomarEmail author


Photochemotherapy (PUVA) combines the use of pso-ralens with long-length (320–400 nm) ultraviolet radiation (UVA), producing a beneficial effect that cannot be reached by the two components separately. Psoralens can be administered orally or topically (solutions, creams, or bath) with posterior exposition to UVA.


Actinic Keratosis PUVA Therapy Phototoxic Reaction Generalize Vitiligo Oral PUVA 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Abdel-Naser MB, Hann SK, Bystryn JC (1997) Oral pso-ralen with UV-A therapy releases circulating growth factor(s) that stimulates cell proliferation. Arch Dermatol 133:1530–1533PubMedCrossRefGoogle Scholar
  2. 2.
    Abd el Fattah A, Aboul-Enein MN, Wassel GM (1982) An approach to treatment of vitiligo by khellin. Dermatologica 165:136–140CrossRefGoogle Scholar
  3. 3.
    Alomar A (1992) Some new treatments of vitiligo vulgaris: phototherapy with topical khellin. dermatology: progress and perspectives. In: Burgdorf and Kats (eds.) Proceedings of the 18th World Congress of Dermatology. New York 517–19Google Scholar
  4. 4.
    Averbeck D (1989) Recent advances in psoralen phototoxic-ity mechanism. Photochem Photobiol 50:859–882PubMedCrossRefGoogle Scholar
  5. 5.
    Bhatnagar A, Kanwar AJ, Parsad D et al (2007) Comparison of systemic PUVA and NB-UVB in the treatment of vitiligo: an open prospective study. J Eur Acad Dermatol Venereol 21:638–642PubMedCrossRefGoogle Scholar
  6. 6.
    Norris G, Hawk JLM, Baker C (1994) British Photodermatology Group guidelines for PUVA. Br J Dermatol 130:246–255CrossRefGoogle Scholar
  7. 7.
    Brücke J, Tanew A, Ortel B et al (1991) Relative efficacy of 335 and 365 nm radiation in photochemotherapy of psoriasis. Br J Dermatol 124:372–374PubMedCrossRefGoogle Scholar
  8. 8.
    Carrascosa JM, Gardeazábal J, Pérez-Ferriols A et al (2005) Consensus document on phototherapy: PUVA therapy and narrow-band UVB therapy. Actas Dermosifiliogr 96:635–658PubMedCrossRefGoogle Scholar
  9. 9.
    Canton M, Caffieri S, Dall'Acqua F (2002) PUVA-induced apoptosis involves mitochondrial dysfunction caused by the opening of the permeability transition pore. FEBS Lett 522:168–172PubMedCrossRefGoogle Scholar
  10. 10.
    Chakrabarti SG, Grimes PE, Minus HR, Kenney JA Jr et al (1982) Determination of trimethylpsoralen in blood, ophthalmic fluids, and skin. J Invest Dermatol 79:374–377PubMedCrossRefGoogle Scholar
  11. 11.
    Collins P, Wainwright NJ, Amorim I et al (1996) 8-MOP PUVA for psoriasis: a comparison of a minimal phototoxic dose-based regimen with a skin-type approach. Br J Dermatol 135:248–254PubMedCrossRefGoogle Scholar
  12. 12.
    Fischer T, Alsins J (1976) Treatment of psoriasis with triox-salen baths and dysprosium lamps. Acta Derm Venereol 56:383–390PubMedGoogle Scholar
  13. 13.
    Freeman K, Watin AP (1984) Deterioration of liver function during PUVA therapy. Photodermatol Photoimmunol Photome 1:147–148Google Scholar
  14. 14.
    Grimes PE (1993) Vitiligo: an overview of therapeutic approaches. Dermatol Clin 11:325–338PubMedGoogle Scholar
  15. 15.
    Grimes PE, Minus HR, Chakrabarti SG (1982) Determination of optimal topical photochemotherapy for vitiligo. J Am Acad Dermatol 7:771–778PubMedCrossRefGoogle Scholar
  16. 16.
    Anon (1994) Guidelines of care for phototherapy and photo-chemotherapy. American Academy of Dermatology Committee on Guidelines of Care. J Am Acad Dermatol 31:643–648CrossRefGoogle Scholar
  17. 17.
    Gupta AK, Anderson TF (1987) Psoralen photochemotherapy. J Am Acad Dermatol 17:703–734PubMedCrossRefGoogle Scholar
  18. 18.
    Halpern SM, Anstey AV, Dawe RS (2000) Guidelines for topical PUVA: a report of a workshopof the British photo-dermatology group. Br J Dermatol 142:22–31PubMedCrossRefGoogle Scholar
  19. 19.
    Henseler T, Wolff K, Hönigsmann H et al (1981) Oral 8-meth-oxypsoralen photochemotherapy of psoriasis. The European PUVA study: a cooperative study among 18 European centres. Lancet 1:853–857PubMedCrossRefGoogle Scholar
  20. 20.
    Honig B, Morison WL, Karp D (1994) Photochemotherapy beyond psoriasis. J Am Acad Dermatol 31:775–790PubMedCrossRefGoogle Scholar
  21. 21.
    Ibbotson SH, Dawe RS, Farr PM (2001) The effect of meth-oxsalen dose on ultraviolet-A-induced erythema. J Invest Dermatol 116:813–815PubMedCrossRefGoogle Scholar
  22. 22.
    Ibbotson SH, Farr PM (1999) The time-course of psoralen ultraviolet A (PUVA) erythema. J Invest Dermatol 113:346–350PubMedCrossRefGoogle Scholar
  23. 23.
    Kenney JA Jr (1971) Vitiligo treated by psoralens: a long term follow-up study of permanency of repigmentation. Arch Dermatol 103:475–480PubMedCrossRefGoogle Scholar
  24. 24.
    Kovacs SO (1998) Vitiligo. J Am Acad Dermatol 38:647–666PubMedCrossRefGoogle Scholar
  25. 25.
    McNeely W, Goa KL (1998) 5-Methoxypsoralen. A review of its effects in psoriasis and vitiligo. Drugs 56:667–690PubMedCrossRefGoogle Scholar
  26. 26.
    Melski JW, Tanenbaum L, Parrish JA (1989) Oral methox-salen photochemotherapy for the treatment of psoriasis: a cooperative clinical trial. 1977. J Invest Dermato l92:153SCrossRefGoogle Scholar
  27. 27.
    Middelkamp-Hup MA, Pathak MA, Parrado C (2004) Orally administered Polypodium leucotomus extract decreases pso-ralen-UVA-induced phototoxicity, pigmentation, and damage of human skin. J Am Acad 50:41–49CrossRefGoogle Scholar
  28. 28.
    Morison WL, Marwaha S, Beck L (1997) PUVA-induced phototoxicity: incidence and causes. J Am Acad Dermatol 36:183–185PubMedCrossRefGoogle Scholar
  29. 29.
    Nijsten TE, Stern RS (2003) The increased risk of skin cancer is persistent after discontinuation of psoralen + ultraviolet A: a cohort study. J Invest Dermatol 121:252–258PubMedCrossRefGoogle Scholar
  30. 30.
    Njoo MD, Westerhof W, Bos JD et al (1999) The development of guidelines for the treatment of vitiligo. Clinical Epidemiology Unit of the Istituto Dermopatico dell'Immacolata-Istituto di Recovero e Cura a Carattere Scientifico (IDI-IRCCS) and the Archives of Dermatology. Arch Dermatol 135(12): 1514–1521PubMedCrossRefGoogle Scholar
  31. 31.
    Orecchia G, Perfetti L (1992) Photochemotherapy with topical khellin and sunlight in vitiligo. Dermatology 184:120–123PubMedCrossRefGoogle Scholar
  32. 32.
    Ortel B, Tanew A, Höningsmann H (1986) Vitiligo treatment. Curr Probl Dermatol 15:256–271Google Scholar
  33. 33.
    Ortel B, Tanew A, Höningsmann H (1988) Treatment of vit-iliogo with Khellin and ultraviolet A. J Am Acad Dermatol 18:693–701PubMedCrossRefGoogle Scholar
  34. 34.
    Parrish JA, Fitzpatrick TB, Tanenbaum L et al (1974) Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light. N Engl J Med 291:1207–1211PubMedCrossRefGoogle Scholar
  35. 35.
    Parrish JA, Fitzpatrick TB, Shea C et al (1976) Photochemotherapy of vitligo. Arch Dermatol 112:1531–1534PubMedCrossRefGoogle Scholar
  36. 36.
    Parsad D, Kanwar AJ, Kumar B (2006) Psoralen-ultraviolet A vs. narrow-band ultraviolet B phototherapy for the treatment of vitiligo. J Eur Acad Dermatol Venereol 20:175–177PubMedCrossRefGoogle Scholar
  37. 37.
    Pathak MA, Fitzpatrick TB (1992) The evolution of photo-chemotherapy with psoralens and UVA (PUVA): 2000 BC to 1992 AD. J Photochem Photobiol B 14:3–22PubMedCrossRefGoogle Scholar
  38. 38.
    Pathak MA, Mosher DB, Fitzpatrick TB (1984) Safety and therapeutic effectiveness of 8-methoxypsoralen, 4,5′,8-trimethylpsoralen, and psoralen in vitiligo. Natl Cancer Inst Monogr 66:165–173PubMedGoogle Scholar
  39. 39.
    Schmutz JL, Jeanmougin M, Martin S et al (2000) [Recommendations of the French Society of Photodermatology for systemic PUVA therapy in psoriasis vulgaris. French Society of Photodermatology] Ann Dermatol Venereol 127:753–759PubMedGoogle Scholar
  40. 40.
    Shaffrali F, Gawkrodger D (2000) Management of vitiligo. Clin Exp Dermatol 25:575–579PubMedCrossRefGoogle Scholar
  41. 41.
    Stern RS, Nichols KT, Vakeva LH (1997) Malignant melanoma in patients treated for psoriasis with methoxalen (pso-ralen) and ultraviolet A radiation (PUVA). N England J Med 336:1041–1045CrossRefGoogle Scholar
  42. 42.
    Stolk L, Siddiqui AH, Cormane RH (1981) Serum levels of trimethylpsoralen after oral administration. Br J Dermatol 104:443–445PubMedCrossRefGoogle Scholar
  43. 43.
    Taneja A (2002) Treatment of vitiligo. J Dermatolog Treat 13:19–25PubMedCrossRefGoogle Scholar
  44. 44.
    Tanew A, Ortel B, Hönigsmann H (1999) Half-side comparison of erythemogenic versus suberythemogenic U VA doses in oral photochemotherapy of psoriasis. J Am Acad Dermatol 41:408–413PubMedCrossRefGoogle Scholar
  45. 45.
    Westerhof W, Nieuweboer-Krobotova L (1997) Treatment of vitiligo with UV-B radiation vs topical psoralen plus UV-A. Arch Dermatol 133:1525–1528PubMedCrossRefGoogle Scholar
  46. 46.
    Wu CS, Lan CC, Wang LF et al (2007) Effects of psoralen plus ultraviolet A irradiation on cultured epidermal cells in vitro and patients with vitiligo in vivo. Br J Dermatol 156:122–129PubMedCrossRefGoogle Scholar
  47. 47.
    Yones SS, Palmer RA, Garibaldinos TM (2007) Randomized double-blind trial of treatment of vitiligo: efficacy of pso-ralen-UV-A therapy vs Narrowband-UV-B therapy. Arch Dermatol 143:578–584PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2010

Authors and Affiliations

  1. 1.Department of Dermatology, Respiratory MedicineHospital de la Santa Creu I Sant PauBarcelonaSpain

Personalised recommendations